What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Disease
- Surgery
Jean Sibilia focuses on Internal medicine, Surgery, Rheumatoid arthritis, Gastroenterology and Immunology.
His study in Rheumatology, Randomized controlled trial, Prospective cohort study, Adverse effect and Rituximab are all subfields of Internal medicine.
His Surgery study combines topics in areas such as Pulmonary hypertension, Adalimumab, Tocilizumab and Infliximab.
The study incorporates disciplines such as Physical therapy, Rheumatism and Arthritis in addition to Rheumatoid arthritis.
His studies in Gastroenterology integrate themes in fields like Scleroderma, Lupus nephritis, Lymphoma and Interstitial lung disease.
His biological study spans a wide range of topics, including Odds ratio, Allele and Genetic predisposition.
His most cited work include:
- Early Detection of Pulmonary Arterial Hypertension in Systemic Sclerosis A French Nationwide Prospective Multicenter Study (605 citations)
- Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjögren’s syndrome (462 citations)
- Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage (411 citations)
What are the main themes of his work throughout his whole career to date?
Jean Sibilia mainly investigates Internal medicine, Rheumatoid arthritis, Immunology, Surgery and Arthritis.
His work carried out in the field of Internal medicine brings together such families of science as Gastroenterology and Physical therapy.
His Rheumatoid arthritis research is multidisciplinary, incorporating perspectives in Methotrexate and Abatacept, Rituximab.
His Immunology study is mostly concerned with Autoimmune disease, Autoantibody, Antibody, Autoimmunity and Connective tissue disease.
His Autoimmune disease study combines topics from a wide range of disciplines, such as Systemic disease and Immunopathology.
His biological study spans a wide range of topics, including Etanercept and Infliximab.
He most often published in these fields:
- Internal medicine (42.70%)
- Rheumatoid arthritis (26.67%)
- Immunology (25.59%)
What were the highlights of his more recent work (between 2016-2021)?
- Internal medicine (42.70%)
- Rheumatoid arthritis (26.67%)
- Immunology (25.59%)
In recent papers he was focusing on the following fields of study:
Internal medicine, Rheumatoid arthritis, Immunology, Cohort and Disease are his primary areas of study.
Internal medicine is often connected to Gastroenterology in his work.
His research in Rheumatoid arthritis intersects with topics in Odds ratio, Discontinuation, Abatacept and Arthritis.
His research investigates the connection between Cohort and topics such as Systemic lupus erythematosus that intersect with problems in Lupus erythematosus, Adverse effect and Pharmacovigilance.
His Disease study also includes
- Dermatology that intertwine with fields like Muscle biopsy,
- Polymyositis together with Autoantibody,
- Dermatomyositis together with Creatine kinase, Antisynthetase syndrome, Biomarker and Retrospective cohort study.
His Tocilizumab research integrates issues from Concomitant, Surgery and Incidence.
Between 2016 and 2021, his most popular works were:
- MUC5B Promoter Variant and Rheumatoid Arthritis with Interstitial Lung Disease. (117 citations)
- Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2). (95 citations)
- Shared genetic predisposition in rheumatoid arthritis-interstitial lung disease and familial pulmonary fibrosis. (70 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Disease
- Cancer
His scientific interests lie mostly in Internal medicine, Immunology, Rheumatoid arthritis, Rituximab and Systemic lupus erythematosus.
His study connects Case-control study and Immunology.
His Rheumatoid arthritis research incorporates elements of Interstitial lung disease and Arthritis.
In his work, Gastroenterology is strongly intertwined with Risk factor, which is a subfield of Arthritis.
His Rituximab research incorporates themes from Belimumab, Randomized controlled trial, Discontinuation and Cyclophosphamide.
Jean Sibilia interconnects Adalimumab, Pharmacovigilance, Adverse drug reaction, Infliximab and Etanercept in the investigation of issues within Systemic lupus erythematosus.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
